Crown Bioscience Appoints Michael Prosser as Chief Business Officer, Illustrating New Investment in Business Leadership

SAN DIEGO, July 28, 2022–(BUSINESS WIRE)–Crown Bioscience, a JSR Life Sciences company, today announced that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) position and investing more in business skills.

This press release contains multimedia elements. View the full press release here:

Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for more than a decade in a variety of operational and commercial leadership positions, most recently serving as Senior Vice President, Commercial and Strategic Development. (Photo: BusinessWire)

Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for more than a decade, where he held various operational and commercial management positions. Most recently, he held the position of Senior Vice President of Business and Strategic Development.

The company’s continued growth has resulted in the creation of three new positions within the sales force who will report to Mr. Prosser. Alex Slater, who joined the company last year, leads APAC’s business development as vice president of global business development; dr. Jonny McMichael named vice president of customer experience and support; and dr. Achim Quandt joined the company as Executive Director of Product Management.

“Crown Bioscience has experienced significant growth in recent years, consistently exceeding its annual growth target, and in fiscal 2021 we were very pleased with booking growth of over 40%,” said CEO, Armin Spura. “With these changes announced today and Michael’s continued leadership, we are confident that we will build a commercial team that optimally positions Crown Bioscience for our next growth phase.”

Michael Prosser, CBO, said: “It is an honor to be asked to lead the next phase of Crown Bioscience’s business growth. Our success to date is directly attributable to our relentless focus on customer experience, product innovation and setting new industry-leading quality standards, and I am delighted to work closely with this new team and structure as we strive to continuously improve all these areas. .”

The company gained more than 400 new customers in fiscal 2021 and to meet this increased demand it has accelerated investments in its global network, with renovations now completed at APAC labs and in particular the creation of a joint venture with sister company MBL in Japan. Parallel investments are also planned in Europe and the United States for site expansions and strategic acquisitions.


About Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology and immune-mediated inflammatory diseases. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the largest commercially available PDX collection in the world market. Crown Bioscience helps deliver superior drug candidates so patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the United States, Europe and Asia. For more information:

The text of the press release resulting from a translation may under no circumstances be regarded as official. The only authentic version of the press release is that of the press release in the original language. The translation will always have to be compared with the source text, which sets a precedent.

Check out the source version at


Crown Bioscience
Louise Stenson

Leave a Comment